Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 304 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HPV Infections Clear all

Conditions: Verruca Vulgaris
Interventions: Liquid nitrogen and cantharidin, Liquid nitrogen and topical placebo; Drug
Lead sponsor: North Idaho Dermatology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Coeur d'Alene, Idaho

Conditions: Neoplasms, Squamous Cell, Papillomavirus Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Cervical Cancer, Head and Neck Cancer, Anal Cancer
Interventions: RTX-321; Drug
Lead sponsor: Rubius Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
Interventions: HspE7, therapeutic conventional surgery, laboratory biomarker analysis; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 17 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Genital Warts, Perianal Warts
Interventions: NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Fountain Valley, California • Lomita, California • San Diego, California + 11 more

Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Interventions: Best Practice, HPV Self-Collection, Informational Intervention, Patient Navigation Program; Other · Procedure · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 30 Years to 64 Years · Female only
Enrollment: 802 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Lexington, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more

Conditions: Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
Interventions: Pembrolizumab (KEYTRUDA®) and PDS0101; Combination Product
Lead sponsor: PDS Biotechnology Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 18
States / cities: Greenbrae, California • San Francisco, California • Jacksonville, Florida + 15 more

Conditions: Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions: VP-102 and applicator, Placebo; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more

Conditions: Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, High-Grade Squamous Intraepithelial Lesions
Interventions: Biospecimen Collection, Questionnaires; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Condyloma
Interventions: Leukocyte Interleukin, Injection 200IU, Leukocyte Interleukin, injection 400IU; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Vulvar Intraepithelial Neoplasia, Condylomata Acuminata
Interventions: CUSA (Cavitronic Ultrasonic Surgical Aspirator); Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Common Wart
Interventions: A-101 Topical Solution, A-101 Vehicle Solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 16
States / cities: Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 13 more

Conditions: Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
Interventions: Artesunate ointment, Placebo; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Papillomavirus Infections
Interventions: 851B; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 22
States / cities: Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more

Conditions: Influenza Vaccine, Papillomavirus Infection, Pertussis
Interventions: Vaccination Program; Other
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 26 Years · Female only
Enrollment: 3,988 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Burlington, North Carolina • Durham, North Carolina • Raleigh, North Carolina

Conditions: Infection, Precancerous Condition
Interventions: Gardasil; Biological
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more

Conditions: Human Papillomavirus Infection
Interventions: Enhancing Accessibility to Health Care, Informational Intervention, Interview, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 26 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Mutation, Head and Neck Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Head and Neck Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions: BGJ398; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infections, Papillomavirus
Interventions: Cervarix™, Havrix™-based investigational formulation; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 18,729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 50
States / cities: Birmingham, Alabama • Fountain Valley, California • San Diego, California + 39 more

Conditions: Human Papillomavirus Infection
Interventions: Compliance, Message sidedness; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 11 Years to 15 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Papillomavirus Infections
Interventions: 9vHPV Vaccine, Placebo (Saline for Injection); Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 6,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Northridge, California • Rialto, California • Simi Valley, California + 28 more

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
Interventions: PVX4 Combination Product, Placebo Control; Combination Product · Other
Lead sponsor: PapiVax Biotech, Inc.; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Infections, Papillomavirus
Interventions: HPV 16/18 VLP AS04; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 30 Years · Female only
Enrollment: 776 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 17
States / cities: San Francisco, California • Augusta, Georgia • Bardstown, Kentucky + 13 more

Conditions: N/A - Healthy Subjects
Interventions: short videos related to HPV and the HPV vaccine, CDC HPV Fact Sheet; Other
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years to 26 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: East Lansing, Michigan

Search by objective public record fields.

A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin

Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)

Safety Study of Multikine in the Treatment of Perianal Warts

Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

Promoting HPV Vaccination Among Young Adults in Texas

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

Engaging College Students in Developing and Testing a Video-based Intervention for HPV Vaccination Promotion